Stop, Reduce or Stay on Antipsychotics After First-Episode Psychosis?

Why It Matters

The findings challenge the one‑size‑fits‑all guideline of 1‑2 years maintenance, urging clinicians to weigh relapse risk against long‑term quality of life and functional outcomes.

Key Takeaways

• Higher relapse risk in first year after dose reduction
• Researcher‑rated functioning improves after three years of tapering
• Patient‑reported functioning shows no difference between strategies
• BMI increased in dose‑reduction group despite lower medication
• Personalized, shared decision‑making essential for antipsychotic management

Pulse Analysis

First‑episode psychosis (FEP) marks a critical juncture where clinicians must balance the proven efficacy of antipsychotics against their notorious side‑effects. Traditional guidelines, such as those from NICE, recommend at least one to two years of maintenance therapy to curb relapse. Yet weight gain, sedation, and metabolic disturbances can erode the very recovery patients strive for, prompting a growing interest in dose‑reduction strategies that prioritize functional outcomes and patient autonomy. This tension reflects a broader shift in psychiatry toward individualized care models that value quality of life as much as symptom control.

The UCL‑led trial, conducted between 2017 and 2023, randomized 179 participants to maintenance and 168 to a dose‑reduction or discontinuation pathway. Short‑term results were stark: the reduction arm experienced a 2.8‑fold increase in relapse odds, a modest but statistically significant drop in EQ‑5D‑VAS scores, and a higher mortality count, including suicides. Over a four‑year horizon, however, researcher‑rated Global Assessment of Functioning scores rose by six points and PANSS scores fell, suggesting that, once the initial risk period passed, lower medication exposure may foster better functional recovery. Notably, benefits emerged earlier in women, while patient‑reported WHODAS‑2 scores showed no divergence, underscoring the disparity between clinician and lived‑experience assessments.

For practice, the study reinforces the need for a collaborative, risk‑stratified approach. Routine medication reviews, transparent discussions about side‑effects, and clear relapse‑monitoring protocols can empower patients to make informed choices. Primary‑care providers should receive training on safe tapering and early warning signs, while health systems must develop guidelines that integrate both physical and mental health metrics. Future research should explore biomarkers that predict who will thrive on reduced dosing, and address gaps such as ethnic diversity and metabolic outcomes, ensuring that personalized psychosis care becomes the new standard.